Related Experiment Videos
[Clostridium difficile infection].
Mónica Ivonne Portillo-López1, M Alejandro Castellanos-Urdaibay, Elena Cortés-Nava
1Instituto Mexicano de Investigación Clínica, Durango 216, México, D.F. C.P. 06700.
Gaceta Medica De Mexico
|March 12, 2002
Summary
Clostridium difficile infection causes diarrhea and colitis, often after antibiotic use. Treatment with metronidazole or vancomycin may be needed, but relapses can occur.
Area of Science:
- Microbiology
- Infectious Diseases
Context:
- Clostridium difficile is an anaerobic intestinal bacterium.
- It produces toxins A and B, leading to intestinal damage and diarrhea.
- Antibiotic therapy disrupts normal gut flora, allowing C. difficile overgrowth.
Purpose:
- To describe the characteristics of Clostridium difficile.
- To explain the pathogenesis of C. difficile-associated diseases.
- To outline current therapeutic approaches and challenges.
Summary:
- Clostridium difficile, an anaerobic bacillus with spores, resides in the intestines.
- Toxigenic strains produce enterotoxin (A) and cytotoxin (B), causing cytopathic effects on the intestinal mucosa.
- Disease spectrum ranges from antibiotic-associated diarrhea to severe pseudomembranous colitis.
- Therapeutic options include metronidazole and vancomycin, though relapses are common.
Impact:
- Highlights the role of C. difficile in antibiotic-associated gastrointestinal illness.
- Emphasizes the risk of C. difficile overgrowth following broad-spectrum antibiotic use.
- Underscores the challenge of recurrent C. difficile infections and the need for effective therapies.